Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3631-3652

  Rowinsky, Eric K ^a   Windle, Jolene J ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ARTICLE; CANCER GENETICS; COLON ADENOCARCINOMA; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 0032704708     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3631     Document Type: Article

References (175)

1. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
2. Bollag G, McCormick F: Regulators and effectors of ras proteins, Ann Rev Cell Biol 7:601-632, 1991
3. Barbacid M: ras genes. Ann Rev Biochem 56:779-827, 1987
4. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366:643-654, 1993
5. Lowy DR, Willumsen BM: Function and regulation of Ras. Ann Rev Biochem 62:851-891, 1993
6. Leonard DM: Ras farnesyltransferase: A new therapeutic target. J Med Chem 40:2971-2990, 1997
7. Ellis RW, Defeo D, Shih TY, et al: The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 292:506-511, 1981
8. Ruta M, Wolford R, Dhar R, et al: Nucleotide sequence of the two rat cellular H-ras genes. Mol Cell Biol 6:1706-1710, 1986
9. Shimizu K, Goldfarb M, Suard Y, et al: Three human transforming genes are related to the viral oncogenes. Proc Natl Acad Sci USA 80:2112-2116, 1983
10. Gibbs JB: Lipid modifications of proteins in the Ras superfamily, in Birnbaumer L, Dickey B (eds): GTPases in Biology. New York, NY, Springer-Verlag, 1993, pp 335-344
11. Hancock JF, Magee AI, Childs JE, et al: All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167-1177, 1989
12. Hancock JF, Paterson H, Marshall CJ: A polybasic domain or palmitoylation is required for the addition of the CAAX motif to localize p21 to the plasma membrane. Cell 63:133-139, 1990
13. Jackson JH, Cochrane CG, Bourne JR, et al: Farnesyl modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad U S A 87:3042-3046, 1990
14. Kato K, Cox AD, Hisaka MM, et al: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 89:6403-6407, 1992
15. Khosravi-Far R, Der CJ: The Ras signal transduction pathway. Cancer Metastasis Rev 13:67-89, 1994
16. McCormick F: Activators and effectors of ras p21 proteins. Curr Opin Genet Dev 4:71-76, 1994
17. Pazin MJ, Williams LT: Triggering signaling cascades by receptor tyrosine kinases. Trends Biochem Sci 17:374-378, 1992
18. McCormick F: How receptors turn Ras on. Nature 363:15-17, 1993
19. Clark GJ, Der CJ: Ras proto-oncogene activation in human malignancy, in Markers CT, Garrett, Sell S (eds): Cellular Cancer. Totowa, NJ, Humana Press, 1995, pp 17-52
20. Tahey M, McCormick F: A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238:542-545, 1987
21. ras proteins and their GTPase activating proteins. Cancer Surv 12:25-42, 1992
22. Khosravi-Far R, Campbell S, Rossman KL, et al: Increasing complexity of Ras signal transduction: Involvement of Rho family proteins. Adv Cancer Res 72:57-107, 1998
23. McCormick F: Ras biology in atomic detail. Nature Struct Biol 3:653-655, 1996
24. Stokoe D, MacDonald SG, Cadwallader K, et al: Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463-1467, 1994
25. Leevers SJ, Paterson HF, Marshall CJ: Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369:411-414, 1994
26. Pritchard C, McMahon M: Raf revealed in life-or-death decisions. Nature Genet 16:214-215, 1997
27. Tamada M, Hu CD, Kariya K, et al: Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation. Oncogene 15:2959-2964, 1997
28. Morrison DK, Cutler RE Jr: The complexity of Raf-1 regulation. Curr Opin Cell Biol 9:174-179, 1997
29. Marshall CJ: Cell signalling: Raf gets it together. Nature 383:127-128, 1996
30. Stanton VP Jr, Nichols DW, Laudano AP, et al: Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol Cell Biol 9:639-647, 1989
31. Heidecker G, Huleihel M, Cleveland JL, et al: Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10:2503-2512, 1990
32. Burgering BMT, Bos JL: Regulation of Ras-mediated signaling: More than one way to skin a cat. Trends Biochem Sci 20:18-22, 1995
33. Kolch W, Heidecker G, Lloyd P, et al: Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349:426-428, 1991
34. Schaap D, van der Wal J, Howe LR, et al: A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J Biol Chem 268:20232-20236, 1993
35. Bonner TI, Kerby SB, Sutrave P, et al: Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol 5:1400-1407, 1985
36. Cowley S, Paterson H, Kemp P, et al: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-852, 1994
37. Mansour SJ, Matten WT, Hermann AS, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-970, 1994
38. Stang S, Bottorff D, Stone JC: Interaction of activated Ras with Raf-1 alone may be sufficient for transformation of rat2 cells. Mol Cell Biol 17:3047-3055, 1997
39. Khosravi-Far R, Solski PA, Clark GJ, et al: Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 15:6443-6453, 1995
40. Oldham SM, Clark GJ, Gangarosa LM, et al: Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc Natl Acad Sci U S A 93:6924-6928, 1996
41. Prendergast GC, Gibbs JB: Pathways of Ras function: Connections to the actin cytoskeleton. Adv Cancer Res 62:19-64, 1993
42. Joneson T, White MA, Wigler MH, et al: Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of Ras. Science 271:810-812, 1996
43. Ridley AJ, Paterson HF, Johnston CL, et al: The small GTP-binding protein Rac regulates growth-factor induced membrane ruffling. Cell 70:401-410, 1992
44. Ridley AJ, Hall A: The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389-399, 1992
45. Rodriguez-Viciana P, Warne PH, Dhand R, et al: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532, 1994
46. Lange-Carter CA, Pleiman CM, Gardner AM, et al: A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 260:315-319, 1993
47. Lange-Carter CA, Johnson GL: Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 265:1458-1461, 1994
48. Minden A, Lin A, McMahon M, et al: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723, 1994
49. Yan M, Dai T, Deak JC, et al: Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372:798-800, 1994
50. Lin M, McMahon M, Lange-Carter C, et al: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723, 1994
51. Dérijard B, Hibi M, Wu I-H, et al: JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037, 1994
52. Johnson R, Spiegelman B, Hanahan D, et al: Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16:4504-4511, 1996
53. Hunter T: Oncoprotein networks. Cell 88:333-346, 1997
54. Carpenter CL, Cantley LC: Phosphoinositide kinases. Curr Opin Cell Biol 8:153-158, 1996
55. Yan J, Roy S, Apolloni A, et al: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273:24052-24056, 1998
56. Kodaki T, Woscholski R, Hallberg B, et al: The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 4:798-806, 1994
57. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, et al: Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15:2442-2451, 1996
58. Rodriguez-Viciana P, Warne PH, Khwaja A, et al: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457-467, 1997
59. Keely PJ, Westwick JK, Whitehead IP, et al: Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390:632-636, 1997
60. Tresini M, Mawal-Dewan M, Cristofalo VJ, et al: A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts. Cancer Res 58:1-4, 1998
61. ras- and phosphatidylinositol 3′-kinase-dependent pathway. Cell Growth Differ 8:1257-1266, 1997
62. Yao R, Cooper GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003-2006, 1995
63. Kennedy SG, Wagner AJ, Conzen SD, et al: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11:701-713, 1997
64. Khwaja A, Rodriguez-Viciana P, Wennstrom S, et al: Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16:2783-2793, 1997
65. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385:544-548, 1997
66. Franke TF, Kaplan DR, Cantley LC: PI3K: Downstream AKTion blocks apoptosis. Cell 88:435-437, 1997
67. Chung J, Grammer TC, Lemon KP, et al: PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 370:71-75, 1994
68. Banerjee P, Ahmad MF, Grove JR, et al: Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase. Proc Natl Acad Sci U S A 87:8550-8554, 1990
69. Chung J, Kuo CJ, Crabtree GR, et al: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69:1227-1236, 1992
70. Lane HA, Fernandez A, Lamb NJC, et al: p70s6k function is essential for G1 progression. Nature 363:170-172, 1993
71. Shih C, Weinberg RA: Isolation of transforming sequence from a human bladder carcinoma cell line. Cell 29:161-169, 1982
72. Krontiris T, Cooper GM: Transforming activity in human tumor DNAs. Proc Natl Acad Sci U S A 78:1181-1184, 1981
73. Perucho M, Goldfarb M, Shimizu K, et al: Human tumor-derived cell lines contain common and different transforming genes. Cell 27:467-476, 1981
74. Casey PJ: p21 Ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A 86:8323-8327, 1989
75. Beaupre DM, Kurzrock R: RAS and leukemia: From basic mechanisms to gene-directed therapy. J Clin Oncol 17:1071-1079, 1999
76. Gelb MH: Protein prenylation, et cetera: Signal transduction in two dimensions. Science 275:1750-1751, 1997
77. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochim Biophys Acta 1333:F51-F71, 1997
78. Omer CA, Anthony NJ, Buser-Doepner CA, et al: Farnesyl: Proteintransferase inhibitors as agents to inhibit tumor growth. Biofactors 6:359-366, 1997
79. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann Rev Pharmacol Toxicol 37:143-166, 1997
80. Yamane HK, Farnsworth CC, Xie HY, et al: Brain G protein gamma subunits contain all-trans-geranylgeranylcysteine methyl ester at their carboxyl termini. Proc Natl Acad Sci U S A 87:5868-5872, 1990
81. Schafer WR, Kim R, Sterne R, et al: Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245:379-385, 1989
82. Hancock JF, Cadwallader K, Marshall CJ: A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J 10:641-646, 1991
83. Duder T, Gelb MH: Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes. J Biol Chem 271:11541-11547, 1996
84. Ghomashchi F, Zhang X, Liu L, et al: Binding of prenylated and polybasic peptides to membranes: Affinities and intervesicle exchange. Biochemistry 34:11910-11918, 1995
85. Zhang FL, Casey PJ: Protein prenylation: Molecular mechanisms and functional consequences. Ann Rev Biochem 65:241-269, 1996
86. ras farnesyl: Protein transferase by cys-AAX tetrapeptides. Cell 62:81-88, 1990
87. ras protein farnesyltransferase. Proc Natl Acad Sci U S A 88:732-736, 1991
88. Park HW, Boduluri SR, Moomaw JF, et al: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 275: 1800-1804, 1997
89. Andres DA, Goldstein JL, Ho YK, et al: Mutational analysis of alpha-subunit of protein farnesyltransferase: Evidence for a catalytic role. J Biol Chem 268:1383-1390, 1993
90. Kumar A, Beresini MH, Dhawan P, et al: Alpha-subunit of farnesyltransferase is phosphorylated in vivo: Effect of protein phosphatase-1 on enzymatic activity. Biochem Biophys Res Commun 222:445-452, 1996
91. Vogt A, Sun J, Qian Y, et al: Burkitt lymphoma Daudi cells contain two distinct farnesyltransterases with different divalent cation requirements. Biochemistry 34:12398-12403, 1995
92. Yokoyama K, Zimmerman K, Scholten MH: Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation. J Biol Chem 272:3944-3952, 1997
93. Clarke S: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61:355-386, 1992
94. Casey PJ, Seabra MC: Protein prenyltransferases. J Biol Chem 271:5289-5292, 1996
95. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetics in vitro. J Biol Chem 266:14603-14610, 1995
96. Armstrong SA, Hannah VC, Goldstein JL, et al: CAAX geranyl-geranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol Chem 270:7864-7868, 1995
97. Cox AD, Hisaka MM, Buss JE, et al: Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol 12:2606-2615, 1992
98. Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:177-178, 1994
99. James GL, Goldstein JL, Pathak RK, et al: PxF, a prenylated protein of peroxisomes. J Biol Chem 269:14182-14190, 1994
100. Symons M: The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Curr Opin Biotechnol 6:668-774, 1995
101. Goldstein JL, Brown MS, Stradley SJ, et al: Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem 266:15575-15578, 1991
102. Sebti SM, Hamilton AD: New approaches to anticancer drug design based on the inhibition of farnesyltransferase. Drug Discov Today 3:26-33, 1998
103. Heimbrook DC, Oliff A: Therapeutic intervention and signaling. Curr Opin Cell Biol 10:284-288, 1998
104. Brown MS, Goldstein JL, Paris KJ, et al: Tetrapeptide inhibitors of protein farnesyltransferase: Amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation. Proc Natl Acad Sci U S A 89:8313-8316, 1992
105. Kohl NE, Mosser SD, deSolms SJ: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937, 1993
106. Kohl NE, Wilson FR, Mosser SD, et al: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 91:9141-9145, 1994
107. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995
108. deSolms SJ, Deana AA, Giulian EA, et al: Pseudodipeptide inhibitors of protein farnesyltransferase. J Med Chem 38:3967-3971, 1995
109. Lerner EC, Qian Y, Hamilton AD, et al: Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270:26770-26773, 1995
110. Nagasu T, Yoshimatsu K, Rowell C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314, 1995
111. Liu M, Bryant MS, Chen J, et al: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58:4947-4956, 1998
112. Mallams AK, Njoroge FG, Doll RJ, et al: Antitumor 8-chlorobenzocycloheptapyridines: A new class of selective, nonpeptidic,. nonsulfhydryl inhibitors of ras farnesylation. Bioorg Med Chem 5:93-99, 1997
113. Njoroge FG, Doll RJ, Vibulbhan B, et al: Discovery of novel nonpeptidic tricyclic inhibitors of Ras farnesyl protein transferase. Bioorg Med Chem 5:101-113, 1997
114. Bishop WR, Bond R, Petrin J, et al: Novel tricyclic inhibitor of farnesyl protein transferase: Biochemical characterization and inhibition of Ras modification in transfected Cos cells. J Biol Chem 270:30611-30618, 1995
115. Leonard DM, Shuler KR, Poulter CJ, et al: Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem 40:192-200, 1997
116. Manne V, Yan N, Carboni JM, et al: Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells. Oncogene 10:1763-1779, 1995
117. Yan N, Ricca C, Fletcher J, et al: Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res 55:3569-3575, 1995
118. Basu TN, Gutmann DH, Fletcher JA, et al: Aberrant regulation of ras proteins in malignant tumour cells from type I neurofibromatosis patients. Nature 356:713-715, 1992
119. ras contributes to malignant tumor growth in von Reckinghausen (type 1) neurofibromatosis. Cell 69:265-273, 1992
120. Tamanoi F, Mitsuzawa H: Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. Methods Enzymol 255:82-91, 1995
121. Kainuma O, Asano T, Hasegawa M, et al: Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas 15:379-383, 1997
122. Venet M, Angibaud P, Sanz G, et al: Synthesis and in-vitro structure-activity relationships of imidazolyl-2-quinolinones as farnesyl protein transferase inhibitors. Proc Am Assoc Cancer Res 39:2171, 1998 (abstr)
123. Todd AV, Applegate TL, Fuery CJ, et al: Farnesyl transferase inhibitor (FTI): Effect on ras activation. Proc Am Assoc Cancer Res 39:2168A, 1998 (abstr)
124. End D, Skrzat S, Devine A, et al: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): Biochemical and cellular effects in H-ras and K-ras dominant systems. Proc Am Assoc Cancer Res 39:1847, 1998 (abstr)
125. Sun J, Qian Y, Hamilton AD, et al: Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473, 1998
126. 2-M enrichment in A549 cells. Cancer Res 57:1846-1850, 1997
127. WAF1/CIP1/SDI1 in a p53-independent manner. J Biol Chem 272:27224-27229, 1997
128. Schwab G, Chavany C, Duroux I, et al: Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci U S A 91:10460-10464, 1994
129. Garcia AM, Rowell C, Ackermann K, et al: Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. Biol Chem 268:18415-18418, 1993
130. James GL, Goldstein JL, Brown MS, et al: Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260:1937-1942, 1993
131. Prendergast GC, Davide JP, deSolms SJ, et al: Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202, 1994
132. Fiordalisi JJ, Rushton BC, Tourssaint LF III, et al: High affinity for FTase and alternative prenylation contribute individually to K-Ras resistance to FTIs. Proc Am Assoc Can Res 40:521, 1999 (abstr)
133. V12 proteins to farnesyltransferase inhibitors in Ratl cells. Proc Natl Acad Sci U S A 93:4454-4458, 1996
134. Jackson JH, Li JW, Buss JE, et al: Polylysine domain of K-ras 4B protein is crucial for malignant transformation. Proc Natl Acad Sci U S A 91:12730-12734, 1994
135. James GL, Brown MS, Cobb MH, et al: Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras transformed Rat-1 cells, but not in untransformed cells. J Biol Chem 269:27705-27714, 1994
136. Lerner EC, Qian Y, Blaskovich MA, et al: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/Raf complexes. J Biol Chem 270:26802-26806, 1995
137. Sun J, Qian Y, Hamilton AD, et al: Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55:4243-4247, 1995
138. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464, 1997
139. Rowell CA, Kowalczyk JJ, Lewis MD, et al: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272:14093-14097, 1997
140. Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15:6613-6622, 1995
141. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57:708-713, 1997
142. Hung W-C, Chaung L-Y: The farnesyltransferase inhibitor FPT inhibitor III upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells. Int J Oncol 12:137-140, 1998
143. Smets G, Van Eyck N, Devine A, et al: R115777, a selective farnesyl protein transferase inhibitor, induces predominately apoptotic activity in C32 melanoma tumor xenografts. Proc Am Assoc Cancer Res 40:522, 1999 (abstr)
144. Du W, Prendergast GC: Activation of the PI3-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208-4212, 1999
145. Gibbs JP: Ras C-terminal processing enzymes: New drug targets? Cell 65:1-4, 1991
146. Miyake M, Mizutani S, Koide H, et al: Unfamesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras.Raf complex in the cytosol. FEBS Lett 378:15-18, 1992
147. Prendergast GC, Davide JP, Lebowitz PF, et al: Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res 56:2626-2632, 1996
148. Skrzat S, Angibaud P, Venet M, et al: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity. Proc Am Assoc Cancer Res 39:2169A, 1998 (abstr)
149. Smets G, Xhonneux B, Cornelissen F, et al: R115777, a selective farnesyl protein transferase inhibitor (FTI), induces anti-angiogenic, apoptotic and anti-proliferative activity in CAPAN-2 and LoVo tumor xenografts. Proc Am Assoc Cancer Res 39:2170A, 1998 (abstr)
150. Kohl NE, Omer CA, Conner MW, et al: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1:792-797, 1995
151. Zujewski J, Horak ID, Bol CJ, et al: A phase I study of farnesyl protein transferase inhibitor, R115777, in advanced cancer. J Clin Oncol (in press)
152. Hudes G, Schol J, Baab J, et al: Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol 18:156a, 1999 (abstr 601)
153. Soignet S, Yao S-L, Britten D, et al. Pharmacokinetics and phramacodynamics of the farnesyl protein transferase inhibitor (L-778, 123) in solid tumors. Proc Am Assoc Can Res 40:3413, 1999 (abstr)
154. Britten CD, Rowinsky E, Yao S-L, et al: The farnesyl protein transferase (FTPase) inhibitor L-778, 123 in patients with solid cancers. Proc Am Soc Clin Oncol 18:155a, 1999 (abstr 597)
155. Adjei AA, Erlichman C, Davis JN, et al: A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer. Proc Am Soc Clin Oncol 18:156a, 1999 (abstr 598)
156. Hurwitz HI, Colvin OM, Petros WP, et al: Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule. Proc Am Soc Clin Oncol 18:156a, 1999 (abstr 599)
157. Eskens F, Awada A, Verweijj J. et al: Phase I and pharmacologic study of continuous daily oral SCH 66336, a novel farnesyl transferase inhibitor, in patients with solid tumors. Proc Am Soc Clin Oncol 18:156a, 1999 (abstr 600)
158. Sinn E, Muller W, Pattengale P, et al: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465-475, 1987
159. Hundley JE, Koester SK, Troyer DA, et al: Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol 17:723-731, 1997
160. Yonish-Rouach E: The p53 tumour suppressor gene: A mediator of a G1 growth arrest and of apoptosis. Experientia 52:1001-1007, 1996
161. Barrington RE, Subler MA, Rands E, et al: A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18:85-92, 1998
162. Donehower LA, Harvey M, Slagle BL, et al: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221, 1992
163. Hancock JF: Prenylation and palmitoylation analysis. Methods Enzymol 25:237-245, 1995
164. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A 95:1369-1374, 1998
165. Skrzat SG, Bowden CR, End DW: Interaction of the farnesyl protein transferase inhibitor R115777 with cytotoxic chemotherapeutics in vitro and in vivo. Proc Am Assoc Cancer Res 40:523, 1999 (abstr)
166. Shi B, Gurnani M, Yaremko B, et al: Enhanced efficacy of the farnesyl protein transferase inhibitor SCH66336 in combination with paclitaxel. Proc Am Assoc Cancer Res 40:524, 1999 (abstr)
167. Grugel S, Finkenzeller G, Weindel K, et al: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270:25915-25919, 1995
168. Rak J, Mitsuhashi Y, Bayko L, et al: Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580, 1995
169. Bernhard EJ, Kao G, Cox AD, et al: The farnesyl transferase inhibitor FTI-277 radiosensitizes H-Ras transformed rat embryo fibroblasts. Cancer Res 56:1727-1730, 1996
170. McKenna WG, Weiss MC, Endlich B, et al: Synergistic effects of the v-myc oncogene with H-Ras on radioresistance. Cancer Res 50:97-102, 1990
171. Von Hoff DD: There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Linda Rosenthal Foundation lecture. Clin Cancer Res 4:1079-1086, 1998
172. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized clinical trial. J Clin Oncol 15:2403-2413, 1997
173. Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. Ann Oncol 9:1047-1052, 1998
174. Shirasawa S, Furuse M, Yokoyama N, et al: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85-88, 1993
175. Plattner R, Anderson MJ, Sato KY, et al: Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci U S A 93:6665-6670, 1996